Zealand Pharma and Helsinn announce the advance of elsiglutide into Phase II for the prevention of chemotherapy-induced diarrhea in cancer patients

First patients dosed in Phase IIa study of novel GLP-2 peptide agonist

06-Mar-2012 - Zealand Pharma A/S and Helsinn announced that the first patients have been dosed in a Phase IIa study of elsiglutide (ZP1846) for the prevention of chemotherapy-induced diarrhea in cancer patients. Elsiglutide is a potent and selective glucagon-like-peptide-2 (GLP-2) agonist invented by Zealand ...

The 5-HT3 Receptor Antagonist Aloxi Launched in Japan

27-Apr-2010 - Helsinn Healthcare SA and Taiho Pharmaceutical Co., Ltd., Japanese licensee of Helsinn's second generation 5-HT3 receptor antagonist palonosetron, announced the launch of Aloxi(R) injection. Aloxi was developed in Japan by Taiho in close cooperation with Helsinn, based on the license agreement ...

Helsinn Announces Completion of its new Stability Centre at its Irish Drug Product Manufacturing Facility

23-Oct-2009 - Helsinn announced the completion of its state of the art Stability Centre at its Helsinn Birex Pharmaceuticals facility in Dublin, Ireland. The new facility which has a total storage capacity of 24 cu meters, contains a range of stability chambers which will operate at ICH conditions of 25 ...

Zealand Pharma and Helsinn Healthcare Sign a Partnering Agreement for ZP1846, a novel GLP-2 agonist

02-Dec-2008 - Zealand Pharma A/S and Helsinn Healthcare SA announced that it has signed a partnering agreement, for the development and worldwide commercialization of ZP1846, a GLP-2 (glucagon-like peptide-2) receptor agonist which provides a novel way to treat chemotherapy-induced diarrhea (CID), a ...

Exelixis and Helsinn Sign Agreement for XL119 (becatecarin)

15-Jun-2005 - Exelixis, Inc. and Helsinn Healthcare S.A. reached an agreement for the development of XL119 (becatecarin). Under the terms of the agreement, Helsinn will pay Exelixis an upfront payment of $4 million and additional milestones up to $21 million. In addition, Helsinn will assume the cost of the ...